Therefore, to see whether targeting arginase activity might be relevant in the treatment of MM we treated Vκ*MYC-bearing mice with arginase inhibitor either alone or in combination with bortezomib, a backbone of most MM therapeutic regimens. The gene discussed is MYC; the disease is Miyoshi myopathy.